Investor Toolkit

Press Release

Lantheus Announces Refinancing of its Debt Facility

Increases available liquidity; positive impact on cash flow
projected to be approximately $5 million per year

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 30, 2017--
Lantheus
Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus
Medical Imaging, Inc. (collectively, “Lantheus” or “the Company”),
today announced the closing of a new $275 million term loan facility
(the “new term loan”) and a new $75 million five-year cash-flow revolver
facility (the “CFR”).

Net proceeds from the new term loan, together with approximately $15
million of cash on hand, were used to retire the remaining outstanding
principal balance on the Company’s previous $365 million term loan
facility and pay accrued interest and related fees and expenses
attributable to the transaction.

The new term loan has an interest rate of LIBOR + 4.50% and retains the
prior term loan’s maturity date of June 2022 as well as its 1% mandatory
amortization per year, adjusted to reflect the new principal amount. The
new term loan was issued at an original issue discount of 99.75%.

The CFR is priced at LIBOR + 3.50% and replaces the $50 million asset
backed loan (“ABL”) facility, which was undrawn at the time of closing
of the refinancing. The CFR carries the same 0.375% unused line fee as
the ABL and has an extended maturity date of March 2022. Funds available
under the CFR may be used for working capital and other general
corporate purposes.

“We remain committed to enhancing the Company’s capital structure,”
commented Jack Crowley, Chief Financial Officer of Lantheus. “This
transaction improves our credit profile, provides additional liquidity
and gives the flexibility needed to effectively capitalize upon our
strategic initiatives. As of closing, our leverage ratio continues to
improve, and we believe the reduction in interest rate and amortization
payments will provide a positive impact on cash flow of approximately $5
million per year over the life of the facility.”

The transaction was led by JPMorgan Chase Bank, N.A., with Citizens
Bank, N.A. and Wells Fargo Securities, LLC acting as joint lead
arrangers.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.Lantheus
Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc.
(“LMI”), a global leader in the development, manufacture and
commercialization of innovative diagnostic imaging agents and products.
LMI provides a broad portfolio of products, including the
echocardiography contrast agent DEFINITY® Vial for
(Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. The
Company is headquartered in North Billerica, Massachusetts with offices
in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” as defined
under U.S. federal securities laws. Forward-looking statements may be
identified by their use of terms such as anticipate, believe, confident,
could, should, estimate, expect, intend, may, plan, predict, project,
target, will and other similar terms. Such forward-looking statements
are subject to risks and uncertainties that could cause actual results
to materially differ from those described in the forward- looking
statements. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of the
date hereof. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by law.
Risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking statements
are discussed in our filings with the Securities and Exchange Commission
(including those described in the Risk Factors section in our Annual
Reports on Form 10-K and our Quarterly Reports on Form 10-Q).